Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
Cancer–testis antigen NY-ESO-1 is one of the most immunogenic tumor antigens defined to date. Spontaneous humoral and CD8+ T-cell responses to NY-ESO-1 are detected in 40–50% of patients with advanced NY-ESO-1-expressing tumors. A clinical trial was initiated to study the immunological effects of in...
Zapisane w:
| Wydane w: | Proc Natl Acad Sci U S A |
|---|---|
| Główni autorzy: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
National Academy of Sciences
2000
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC17318/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11027314/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.220413497 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|
